| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
*
Oklahoma Medical Research Foundation, Oklahoma City, OK 73104;
University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104;
Austin Research Institute, Heidelberg, Victoria, Australia; and
U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK 73104
Autoantibodies directed against spliceosomal proteins are a common and specific feature of systemic lupus erythematosus. These autoantibodies target a collection of proteins, including Sm B, B', D1, D2, and D3. We define the common antigenic targets of Sm D2 and D3 and examine their role in spliceosomal autoimmunity. Our results define nine major common epitopes, five on Sm D2 and four on Sm D3. These epitopes have significantly higher (more basic) isoelectric points than do nonantigenic regions. In fact, this association is of sufficient power to make isoelectric point an excellent predictor of spliceosomal antigenicity. The crystallographic structure of Sm D2 and D3 is now partially described. The anti-Sm D2 and D3 antigenic targets are located on the surface of the respective three-dimensional complexed proteins, thereby suggesting that these epitopes are accessible in the native configuration. All but one of these nine epitopes conspicuously avoid the specific regions involved in intermolecular interactions within the spliceosomal complex. One of the D3 epitopes (RGRGRGMGR) has significant sequence homology with a major antigenic region of Sm D1 (containing a carboxyl-terminal glycine-arginine repeat), and anti-D3 Abs cross-react with this epitope of Sm D1. These results demonstrate that spliceosomal targets of autoimmunity are accessible on native structure surfaces and that cross-reactive epitopes, as well as structural associations of various spliceosomal Ags, may be involved in the induction of autoimmunity in systemic lupus.
This article has been cited by other articles:
|
|
 |
|
  C. Schild-Poulter, A. Su, A. Shih, O. P. Kelly, M. J. Fritzler, R. Goldstein, and R. J. G. Hache Association of autoantibodies with Ku and DNA repair proteins in connective tissue diseases Rheumatology, February 1, 2008; 47(2): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. James, X. Kim-Howard, B. Bruner, M. Jonsson, M. McClain, M. Arbuckle, C. Walker, G. Dennis, J. Merrill, and J. Harley Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus Lupus, June 1, 2007; 16(6): 401 - 409. [Abstract] [PDF]
|
|
|
|
 |
|
 J W Dieker, C C Van Bavel, G Riemekasten, J H Berden, and J van der Vlag The binding of lupus-derived autoantibodies to the C-terminal peptide (83-119) of the major SmD1 autoantigen can be mediated by double-stranded DNA and nucleosomes Ann Rheum Dis, November 1, 2006; 65(11): 1525 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Riemekasten and B. H. Hahn Key autoantigens in SLE Rheumatology, August 1, 2005; 44(8): 975 - 982. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Teerlink ADMA metabolism and clearance Vascular Medicine, July 1, 2005; 10(1_suppl): S73 - S81. [Abstract] [PDF]
|
|
|
|
|
|
T. Teerlink ADMA metabolism and clearance Vascular Medicine, May 1, 2005; 10(2_suppl): S73 - S81. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Mahler, L. M. Stinton, and M. J. Fritzler Improved Serological Differentiation between Systemic Lupus Erythematosus and Mixed Connective Tissue Disease by Use of an SmD3 Peptide-Based Immunoassay Clin. Vaccine Immunol., January 1, 2005; 12(1): 107 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. McClain, C. S. Lutz, K. M. Kaufman, O. Z. Faig, T. F. Gross, and J. A. James Structural availability influences the capacity of autoantigenic epitopes to induce a widespread lupus-like autoimmune response PNAS, March 9, 2004; 101(10): 3551 - 3556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Arbuckle, M. T. McClain, M. V. Rubertone, R. H. Scofield, G. J. Dennis, J. A. James, and J. B. Harley Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus N. Engl. J. Med., October 16, 2003; 349(16): 1526 - 1533. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
